ArticleNephrology (Carlton, Vic.)2016
Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
Article in Nephrology (Carlton, Vic.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.BMC nephrology · 2020Pooled it
- Article
- The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives.Frontiers in immunology · 2025Review
- [Diagnosis and treatment of Minimal Change Disease in adults-2023].Wiener klinische Wochenschrift · 2023Article
- Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Observational
- Rituximab Use for the Treatment of Childhood Nephrotic Syndrome by Canadian Pediatric Nephrologists: A National Survey.Canadian journal of kidney health and disease · 2022Article
- Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia.Frontiers in medicine · 2022Article
- Rituximab Dosing in Glomerular Diseases: A Scoping Review.Canadian journal of kidney health and disease · 2022Article
- Rituximab for Adults With Multi-Drug Resistant Focal Segmental Glomerulosclerosis: A Case Series and Review of the Literature.Canadian journal of kidney health and disease · 2022Article
- Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.BMC nephrology · 2021Article
- Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.Clinical kidney journal · 2021Review
- Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.Clinical and experimental nephrology · 2020Article
- Rituximab for the maintenance of minimal change nephropathy - A report of two pregnancies.Obstetric medicine · 2020Article
- Rituximab use in adult glomerulopathies and its rationale.Jornal brasileiro de nefrologia · 2020Review
- Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab.BMJ case reports · 2018Article
- The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.American journal of nephrology · 2017Article
- Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Nephrology (Carlton, Vic.) · 2016Article
- Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.Glomerular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
Abstract
aimTreatment of frequently relapsing or steroid-dependent minimal change disease (MCD) in children and adults remains challenging. Glucocorticoids and/or other immunosuppressive agents are the mainstay of treatment, but patients often experience toxicity from prolonged exposure and may either become treatment dependent and/or resistant. Increasing evidence suggests that rituximab (RTX) can be a useful alternative to standard immunosuppression and allow withdrawal of maintenance immunosuppressants; however, data on optimal treatment regimens, long-term efficacy and safety are still limited.
methodsWe undertook a prospective study of RTX to allow immunosuppression minimization in 15 young adults with frequently relapsing or steroid-dependent, biopsy-proven MCD. All patients were in remission at the start of treatment and on a calcineurin inhibitor. Two doses of RTX (1 gr) were given 6 months apart. A subset of patients also received an additional dose 12 months later, in order to examine the benefit of re-treatment. Biochemical and clinical parameters were monitored over an extended follow-up period of up to 43 months.
resultsMedian steroid-free survival after RTX was 25 months (range 4-34). Mean relapse frequency decreased from 2.60 ± 0.28 to 0.4 ± 0.19 (P < 0.001) after RTX. Seven relapses occurred, five of which (71%) when CD19 counts were greater than 100 µ. Immunoglobulin levels remained unchanged, and no major side effects were observed throughout the follow-up period.
conclusionsRituximab therapy is effective at maintaining prolonged steroid-free remission and reducing relapse frequency in this group of patients. Our study lends further support for the role of RTX in the treatment of patients with frequently relapsing or steroid-dependent MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.